Annual revenue fell from KRW 10.5 billion in 2023 to KRW 7.21 billion in 2024 (down 31.5% year on year) and KRW 5.26 billion in 2025 (down 27.1% year on year). Revenue declined for two straight years in 2024 and 2025; 2023 was the largest year and 2025 the smallest in the 2023-2025 period.
Over the same span the operating loss widened from KRW 11.8 billion to KRW 15.7 billion and then KRW 17.9 billion, and the operating margin moved from -111.7% to -217.5% and then -340.4%.
For the first nine months of 2025, the company said some CDMO project revenue was recognized later in the year, while R&D spending rose from KRW 4.7 billion to KRW 5.6 billion as EN001 progressed. It also cited industry-wide clinical delays and weaker biotech investment as reasons for fewer client orders.
Media reported the 2025 operating loss of KRW 17.9 billion as the largest annual loss on record. At the end of 2025, total equity of KRW 39.4 billion was entirely attributable to controlling shareholders, and total liabilities were KRW 24.3 billion.
Operating cash flow was KRW -6.44 billion in 2023, KRW -10.1 billion in 2024, and KRW -10.2 billion in 2025. Net loss attributable to controlling shareholders grew from KRW 5.05 billion in 2023 to KRW 15.2 billion in 2024 and KRW 16.1 billion in 2025.
Quarterly revenue fell from KRW 1.55 billion in Q3 2025 and KRW 1.44 billion in Q4 2025 to KRW 309 million in Q1 2026, then rose to KRW 868 million in Q2 2026 and KRW 1.71 billion in Q3 2026.
Operating losses over the same quarters were KRW 4.87 billion in Q1 2026, KRW 4.68 billion in Q2 2026, and KRW 5.02 billion in Q3 2026, and the Q3 2026 loss widened year on year even as revenue rose 10.7%.
Net loss attributable to controlling shareholders peaked at KRW 7.23 billion in Q2 2026 among the last five quarters and narrowed to KRW 5.78 billion in Q3 2026. The four quarters from Q4 2025 through Q3 2026 total KRW 21.8 billion in net losses attributable to controlling shareholders.